|drug518||Bromhexine 8 MG Wiki||0.50|
|drug3373||To assess for development of IgG antibodies against SARS-CoV2 Wiki||0.50|
|drug517||Brief informational infographic Wiki||0.50|
|drug2744||Rapid Antigen Test Wiki||0.50|
|drug2492||Placebo control (non-behavioral infographic) Wiki||0.50|
|drug531||Butterfly iQ Wiki||0.50|
|drug1371||Guduchi Ghan Vati Wiki||0.35|
|drug1503||Hydroxychloroquine Sulfate Regular dose Wiki||0.35|
|drug1502||Hydroxychloroquine Sulfate Loading Dose Wiki||0.35|
|drug1492||Hydroxychloroquine Sulfate Wiki||0.14|
|D003333||Coronaviridae Infections NIH||0.22|
|D012327||RNA Virus Infections NIH||0.18|
|D014777||Virus Diseases NIH||0.05|
There are 4 clinical trials
To create a protocol for treatment of Pakistani patients with SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different quinone drug dosing regimens in controlling SARS-CoV-2 infection for asymptomatic patients.
Description: Percentage of patients who become RT-PCR negative with two RT-PCR tests performed at day 6 and day 7Measure: RT-PCR negative status Time: 6-7 days
Description: Time to progression to next stage of SARS-CoV-2 disease severity indexMeasure: Progression of symptoms Time: 7 days
Description: Time to onset of fever (temperature greater than 100 degree F), cough, or shortness of breath (respiratory rate >22 per minute).Measure: Development of Symptoms Time: 7 days
Description: Drug related adverse events as determined by data safety and monitoring board (DSMB)Measure: Adverse events Time: 7 days
Purpose: To determine the number of asymptomatic individuals who have antibodies to SARS-CoV-2, the virus which causes COVID-19
Description: Presence or absence of IgG antibodies to SARS-CoV2Measure: Percentage of Asymptomatic patients with an IgG response from SARS-CoV-2 infection. Time: at enrollment
Description: swab for presence of SARS-CoV-2 virusMeasure: Percentage of Asymptomatic patients with viral presence of SARS-CoV-2 infection. Time: at enrollment
Coronavirus disease 2019 (Covid-19) has been declared global emergency with immediate safety, preventative and curative measures to control the spread of virus. Confirmed cases are treated with clinical management as they are diagnosed but so far, there is no effective treatment or vaccine yet for Covid-19. With recommended guidelines of AYUSH Ministry, India, the use of Ayurveda for Covid-19 has increased; however, its efficacy and safety in Covid-19 confirmed patients remain unclear. Present study examined the efficacy and safety of one of the recommended Ayurveda drug (Guduchi Ghan Vati) compared with standard care for patients with asymptomatic Covid-19 patients.
Description: Virologic clearance indicates the duration from the first Covid-19 positive result to the first Covid-19 negative resultMeasure: Virologic clearance Time: 21 days
Description: change in the number of patients going from asymptomatic to moderately diseaseMeasure: Change in the number of patients going from asymptomatic to moderately disease Time: 10-days of hospital admission
Description: Total duration of stay in hospital for complete recoveryMeasure: Hospital Stay Time: 21 days
Description: Clinically relevant adverse effects of Guduchi Ghan Vati (Disability, Discomfort reported)Measure: Clinically relevant adverse effects Time: 21-days
The primary objective of this pilot study is to determine the feasibility and effectiveness of a COVID-19 screening program for passengers departing from YVR. This research study is conducted by The University of British Columbia (UBC) and Providence Health Care, sponsored by WestJet and Vancouver Airport Authority. The experimental study investigates point-of-care rapid test device for detecting SARS-CoV-2, the virus responsible for COVID-19. The study is investigating a method of rapid-testing for COVID-19 and will help inform the safest and most efficient way of testing departing passengers prior to security screening at Vancouver International Airport (YVR). This study is also evaluating a new passenger management system.
Description: positive or negative screening resultMeasure: COVID-19 status Time: 15 min
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports